



CMS Formulary ID: 22312
 Changes effective: 1/1/2022

Drug Name	Reason	Alternate Drugs	Tier
AFINITOR DISPERZ 5 MG ORAL TAB SUSP	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	EVEROLIMUS 5MG ORAL TAB SUSP	5
AFINITOR 10 MG ORAL TABLET	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	EVEROLIMUS 10MG ORAL TAB SUSP	5
CHANTIX 1 MG ORAL TABLET	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	VARENICLINE TARTRATE 1MG ORAL TABLET	2
DUREZOL 0.05 % OPHTHALMIC DROPS	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	DIFLUPREDNATE 0.05% OPHTHALMIC DROPS	2
BYSTOLIC 20 MG ORAL TABLET	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	NEBIVOLOL HCL 20 MG ORAL TABLET	2
BYSTOLIC 5 MG ORAL TABLET	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	NEBIVOLOL HCL 5MG ORAL TABLET	2
BYSTOLIC 10 MG ORAL TABLET	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	NEBIVOLOL HCL 10 MG ORAL TABLET	2

CHANTIX 0.5 MG ORAL TABLET	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	VARENICLINE TARTRATE 0.5MG ORAL TABLET	2
AFINITOR DISPERZ 2 MG ORAL TAB SUSP	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	EVEROLIMUS 2MG ORAL TAB SUSP	5
BYSTOLIC 2.5 MG ORAL TABLET	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	NEBIVOLOL HCL 2.5MG ORAL TABLET	2
EPANED 1 MG/ML ORAL SOLUTION	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	ENALAPRIL MALEATE 1MG/ML ORAL SOLUTION	2
PAXIL 10 MG/5 ML ORAL ORAL SUSP	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	PAROXETINE HCL 10MG/5ML ORAL SUSP	4
AFINITOR DISPERZ 3MG ORAL TAB SUSP	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	EVEROLIMUS 3MG ORAL TAB SUSP	5
ZOSTAVAX 19400 UNIT SUBCUTANE. VIAL TAKING PLACE 3/1/2022	REMOVAL DUE TO U.S. MARKET AVAILABILITY (NON SAFETY RELATED)	N/A	